Xanthine Oxidase Mediates Axonal and Myelin Loss in a Murine Model of Multiple Sclerosis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Honorat, Josephe Archie ^a   Kinoshita, Makoto ^a   Okuno, Tatsusada ^a   Takata, Kazushiro ^a   Koda, Toru ^a   Tada, Satoru ^a   Shirakura, Takashi ^c   Fujimura, Harutoshi ^b   Mochizuki, Hideki ^a   Sakoda, Saburo ^b   Nakatsuji, Yuji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c TEIJIN PHARMA LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FEBUXOSTAT; REACTIVE OXYGEN METABOLITE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICROGLIA; MOLECULAR PATHOLOGY; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; AXONS; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MULTIPLE SCLEROSIS; MYELIN SHEATH; REACTIVE OXYGEN SPECIES; THIAZOLES; XANTHINE OXIDASE;

EID: 84881354600     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071329     Document Type: Article

References (43)

1. Compston A, Coles A, (2002) Multiple sclerosis. Lancet 359: 1221-1231.
2. McFarland HF, Martin R, (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919.
3. Lassmann H, Bruck W, Lucchinetti CF, (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218.
4. van Horssen J, Witte ME, Schreibelt G, de Vries HE, (2011) Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 1812: 141-150.
5. LeVine SM, (1992) The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses 39: 271-274.
6. Gilgun-Sherki Y, Melamed E, Offen D, (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251: 261-268.
7. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, et al. (2011) Oxidative damage in multiple sclerosis lesions. Brain 134: 1914-1924.
8. Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A, (2005) Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res 81: 687-695.
9. Ferretti G, Bacchetti T, (2011) Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci 311: 92-97.
10. Ruuls SR, Bauer J, Sontrop K, Huitinga I, Hart BA, et al. (1995) Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56: 207-217.
11. Moriya M, Nakatsuji Y, Miyamoto K, Okuno T, Kinoshita M, et al. (2008) Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis. Neurosci Lett 440: 323-326.
12. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, et al. (2004) Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 146-153.
13. Morel F, Doussiere J, Vignais PV, (1991) The superoxide-generating oxidase of phagocytic cells. Physiological, molecular and pathological aspects. Eur J Biochem 201: 523-546.
14. Abramov AY, Scorziello A, Duchen MR, (2007) Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J Neurosci 27: 1129-1138.
15. Bedard K, Krause KH, (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
16. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, et al. (2012) NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135: 886-899.
17. Qin L, Crews FT, (2012) NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration. J Neuroinflammation 9: 5.
18. Meneshian A, Bulkley GB, (2002) The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 9: 161-175.
19. Berry CE, Hare JM, (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606.
20. Ono T, Tsuruta R, Fujita M, Aki HS, Kutsuna S, et al. (2009) Xanthine oxidase is one of the major sources of superoxide anion radicals in blood after reperfusion in rats with forebrain ischemia/reperfusion. Brain Res 1305: 158-167.
21. Dupont GP, Huecksteadt TP, Marshall BC, Ryan US, Michael JR, et al. (1992) Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. J Clin Invest 89: 197-202.
22. Beetsch JW, Park TS, Dugan LL, Shah AR, Gidday JM, (1998) Xanthine oxidase-derived superoxide causes reoxygenation injury of ischemic cerebral endothelial cells. Brain Res 786: 89-95.
23. Ernst ME, Fravel MA, (2009) Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther 31: 2503-2518.
24. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, et al. (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 76: 1835-1847.
25. Moriya M, Nakatsuji Y, Okuno T, Hamasaki T, Sawada M, et al. (2005) Vitamin K2 ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 170: 11-20.
26. Okuda Y, Okuda M, Bernard CC, (2002) Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol Lett 81: 25-29.
27. Kanzawa T, Sawada M, Kato K, Yamamoto K, Mori H, et al. (2000) Differentiated regulation of allo-antigen presentation by different types of murine microglial cell lines. J Neurosci Res 62: 383-388.
28. Cunha FQ, Assreuy J, Moncada S, Liew FY, (1993) Phagocytosis and induction of nitric oxide synthase in murine macrophages. Immunology 79: 408-411.
29. Beckman JS, Parks DA, Pearson JD, Marshall PA, Freeman BA, (1989) A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Radic Biol Med 6: 607-615.
30. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, et al. (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118: 1532-1543.
31. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, et al. (2009) Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10: 958-964.
32. Gray E, Thomas TL, Betmouni S, Scolding N, Love S, (2008) Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 444: 195-198.
33. Parkinson JF, Mitrovic B, Merrill JE, (1997) The role of nitric oxide in multiple sclerosis. J Mol Med (Berl) 75: 174-186.
34. van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK, et al. (1998) Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 92: 67-75.
35. Juurlink BH, Thorburne SK, Hertz L, (1998) Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia 22: 371-378.
36. Thorburne SK, Juurlink BH, (1996) Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 67: 1014-1022.
37. Jana A, Pahan K, (2007) Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol 2: 184-193.
38. Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA, (2005) Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci U S A 102: 9936-9941.
39. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, et al. (2010) A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 17: 495-499.
40. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, et al. (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95: 675-680.
41. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, et al. (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5: 343-354.
42. Bjartmar C, Wujek JR, Trapp BD, (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206: 165-171.
43. Lopez-Diego RS, Weiner HL, (2008) Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 7: 909-925.